Semaglutide is a GLP-1 receptor agonist studied for weight management, glycemic control, and metabolic optimization. Physician-reviewed. Prescription required.
Semaglutide is a long-acting synthetic analog of GLP-1 (glucagon-like peptide-1) studied for treatment of type 2 diabetes and obesity. Its mechanisms center on activation of GLP-1 receptors throughout the pancreas, gastrointestinal tract, brain, and other tissues — enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways.
Compounded semaglutide is dispensed by our licensed 503A pharmacy partner with a valid physician prescription. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| GLP-1 receptor agonism | Enhanced incretin signaling |
| Glucose-dependent insulin release | Lower blood glucose |
| Glucagon suppression | Reduced hepatic glucose output |
| Slowed gastric emptying | Reduced post-meal glucose spikes |
| Central appetite suppression | Reduced food intake |
| β-cell protection | Sustained insulin production |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Semaglutide protocol candidates in clinical practice:
Weight Management
Individuals with BMI ≥27 with comorbidities or ≥30, seeking physician-supervised GLP-1 therapy.
Type 2 Diabetes
Individuals with T2D seeking GLP-1-based glycemic control under physician supervision.
Cardiovascular Risk Reduction
Individuals with metabolic syndrome or cardiovascular risk factors where GLP-1 therapy may be clinically appropriate.
Metabolic Optimization
Individuals pursuing physician-reviewed metabolic health optimization as part of a comprehensive longevity protocol.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
0.25–2.4 mg/week (physician-titrated)
Administration
Subcutaneous injection (weekly)
Duration
Ongoing with periodic reassessment
Frequency
Once weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.